Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 13/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | JAK2 | O60674 | 1/20 | 0.39 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.39 |
| ▸ | MELK | Q14680 | 1/20 | 0.39 |
| ▸ | STK24 | Q9Y6E0 | 1/20 | 0.39 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.36 |
| ▸ | PARP1 | P09874 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | GLA | P06280 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.34 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30381452 | 0.82 | CHEK1 (0.49) | CHEK1JAK2RPS6KA3MELKSTK24 | |
| SCHEMBL1050400 | 0.82 | CHEK1 (0.49) | CHEK1JAK2RPS6KA3MELKSTK24 | |
| SCHEMBL4243560 | 0.82 | CHEK1 (0.41) | CHEK1KDM4EJAK2RPS6KA3MELK | |
| SCHEMBL1159123 | 0.79 | CHEK1 (0.46) | CHEK1JAK2RPS6KA3MELKSTK24 | |
| SCHEMBL15760946 | 0.79 | CHEK1 (0.43) | CHEK1JAK2RPS6KA3MELKSTK24 | |
| SCHEMBL12960747 | 0.76 | CHEK1 (0.46) | CHEK1JAK2RPS6KA3MELKSTK24 | |
| SCHEMBL15540146 | 0.76 | CHEK1 (0.43) | CHEK1JAK2RPS6KA3MELKSTK24 | |
| SCHEMBL1159567 | 0.75 | JAK2 (0.48) | CHEK1JAK2ROCK2 | |
| SCHEMBL1159618 | 0.75 | JAK2 (0.49) | CHEK1JAK2ROCK2 | |
| SCHEMBL4246806 | 0.74 | ZAP70 (0.48) | KDM4EALDH1A1GLAPOLBRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110053897-A1 | COMPOUNDS AND COMPOSITIONS AS SYK KINASE INHIBITORS | IRM LLC (BM) | 2011-03-03 | — | — | US | disclosed |
| US-20110003798-A1 | COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS | IRM LLC (BM) | 2011-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110053897-A1 | COMPOUNDS AND COMPOSITIONS AS SYK KINASE INHIBITORS | SYK, BTK, LYN | CHEK1 427/4885KDM4E 1659/4885JAK2 19/4885 |
| US-20110003798-A1 | COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS | FYN, SYK, RET | CHEK1 900/4885KDM4E 2223/4885JAK2 63/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.